Riociguat Bayer, Riociguat Bayer, Placebo for riociguat, Riociguat Bayer
14308
Phase 2 small_molecule active
Quick answer
Riociguat Bayer, Riociguat Bayer, Placebo for riociguat, Riociguat Bayer for Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD) is a Phase 2 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active